GHRS Stock Analysis: Buy, Sell, or Hold?
GHRS - GH Research PLC Ordinary Shares
$22.94
0.08 (0.35%)
▲
5d:
-3.78%
30d:
-18.28%
90d:
-12.34%
HOLD
MODERATE Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When GHRS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: GHRS shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: GHRS shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: GHRS is currently trading at $22.94, which is considered oversold relative to its 30-day fair value range of $25.81 to $28.81.
Technical Outlook: Technically, GHRS is in a uptrend. The price is currently testing key support at $22.36. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: GHRS scores 35/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $42.89 (+87.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, GHRS is in a uptrend. The price is currently testing key support at $22.36. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: GHRS scores 35/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $42.89 (+87.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$25.81 -
$28.81
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (35/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 87.0% below Wall St target ($42.89)
Trading Range Analysis
30-Day Trading Range
$25.81 -
$28.81
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$22.36
Resistance Level
$28.50
Current Trend
Uptrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-12.40
Wall Street Target
$42.89
(+87.0%)
Share & Embed Analysis
Last updated: October 03, 2026 7:39 AM ET
Data refreshes hourly during market hours. Next update: 8:39 AM
Data refreshes hourly during market hours. Next update: 8:39 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GHRS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$92 | 46 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 65 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$109 | 76 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 65 BUY |
|
SRRK
Scholar Rock Holding Corp |
STRONG BUY
10 analysts |
$70 | 68 BUY |
